Biogen Pharmachem Industries (531752) Q2 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 26/27 earnings summary
3 Nov, 2026Executive summary
Q2 FY26/27 revenue was ₹28.33 lakh and net profit was ₹25.73 lakh; H1 revenue was ₹72.67 lakh and net profit was ₹47.87 lakh.
The Board approved the unaudited standalone results for the quarter and half year ended September 30, 2026.
Financial highlights
Q2 revenue was ₹28.33 lakh vs. a loss of ₹10.49 lakh in Q2 FY25/26; H1 revenue fell to ₹72.67 lakh from ₹143.79 lakh.
Q2 profit before tax and net profit were both ₹25.73 lakh, vs. a loss of ₹49.15 lakh in Q2 FY25/26.
H1 profit before tax and net profit were both ₹47.87 lakh, vs. ₹85.33 lakh in H1 FY25/26.
Segment performance
Operations comprise one segment; no separate segment results were presented.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Biogen Pharmachem Industries
- Revenue contracted sharply as profits narrowed; outlook centered on commodity trading and wind power.531752
Q4 06/07 - FY08 trading contracted sharply, with conflicting reported profit figures and planned wind-power expansion.531752Q4 07/08
- Trading expanded, but a ₹43.33m loss and accumulated-loss risks overshadowed growth plans.531752Q4 08/09
- Net loss narrowed sharply, while preference warrants and corporate advances expanded the balance sheet.531752Q4 09/10
- FY12 loss narrowed, but weak markets constrained revenue and management looked to rebuild turnover.531752Q4 11/12
- Zero operating revenue and a wider FY2012-13 loss contrasted with a sharp rise in investments.531752Q4 12/13
- Nil operating revenue, a ₹1.30 million loss and sharply higher short-term borrowings marked FY14.531752Q4 13/14
- No operations, nil operating revenue, and a ₹1.33m FY15 net loss amid working-capital constraints.531752Q4 14/15
- Nil revenue and working-capital constraints kept operations inactive; FY15/16 net loss was ₹281,764.531752Q4 15/16